Cymabay Therapeutics, Inc.
CBAY
Pharmaceutical Preparations
Mkt Cap
$1.839BPE
-20.41Debt
-Cash
$273.7MEV
-FCF
-$64.19MP/E Ratio
-20.41Debt
-Cash
$273.7MEV
-FCF
-$64.19MCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Sector
ABBV
ABCL
ABT
ABUS
AGIO
AKRO
ALKS
ALNY
ALPN
AMLX
AMPH
AMRN
AMRX
ANAB
ANIP
APLS
ARDX
ARVN
ARWR
AUPH
AVDL
AVTE
AXSM
BBIO
BCYC
BGNE
![BHVN Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>BHVN</text></svg>)
BHVN
BMEA
BMRN
BMY
BPMC
CDMO
CERE
CNTA
COGT
COLL
CORT
CPRX
CRNX
CTLT
CYRX
CYTK
DAWN
DCPH
DVAX
DYN
ELAN
EOLS
EQRX
ETNB
EWTX
FOLD
GERN
HRMY
![HZNP Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>HZNP</text></svg>)
HZNP
ICPT
IDYA
IMGN
INSM
INVA
IONS
IRON
IRWD
![ITCI Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>ITCI</text></svg>)
ITCI
JANX
JAZZ
JNJ
KNSA
KROS
KRTX
KURA
LFCR
![LGND Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>LGND</text></svg>)
LGND
LLY
LQDA
LYEL
MDGL
ME
MGNX
MIRM
MLTX
MNKD
MORF
MRK
MRNS
MRTX
![MRUS Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>MRUS</text></svg>)
MRUS
MRVI
![NATR Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>NATR</text></svg>)
NATR
NRIX
OGN
OLMA
OPK
ORGO
ORIC
![PAHC Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>PAHC</text></svg>)
PAHC
PBAJ
PBH
![PCRX Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>PCRX</text></svg>)
PCRX
PFE
PHAT
PLRX
PNT
PRGO
![PRTA Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>PRTA</text></svg>)
PRTA
PTCT
PTGX
QURE
In the chart Earnings are multiplied by this value.
Earnings Growth -
Earnings Stability -
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 08-2022 | 12-2022 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | - | - | -280% | - | - | - | - | - | - | - |
| ROA | -60% | -130% | -20% | -39% | -53% | -34% | -43% | - | -66% | -18% |
| ROE | -55% | -680% | -32% | -43% | -55% | -36% | -68% | - | -290% | -28% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -46.9%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -4.26%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -98.87%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -47.84%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 08-2022 | 12-2022 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | - | - | - | - | - | - | - |
| Debt Equity | - | - | - | - | - | - | - | - | - | - |
| MIN | ||||||||||
| Graham Stability | - | - | - | - | - | - | - | - | - | - |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -.
What is the Graham’s Stability?
Graham’s Stability measure stands at -.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 08-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Net Income | - | - | - | - | - |
| Stockholders Equity | 37% | -27% | -37% | - | -26% |
| FCF | - | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is -.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is -.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is +7.88%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is -26.66%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -25.86%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is +8.71%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.